Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Company Deals

CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

Fineline Cube Aug 11, 2026
Company Drug

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

Fineline Cube Aug 11, 2026
Company Deals

Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech

Fineline Cube Aug 26, 2022

Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B...

Company Deals

Lab Direct Raises USD 10M in Series A+ to Expand Digital Supply Chain Platform

Fineline Cube Aug 26, 2022

Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in...

Company Deals

Health Plus Receives Strategic Investment from Meinian Onehealth to Drive Healthcare Innovation

Fineline Cube Aug 26, 2022

Beijing-based Health Plus, a third-party digital managed healthcare service platform, has received strategic investment from...

Company Deals

Prismlab China Raises USD 29.1M in Series C for 3D Printing Expansion

Fineline Cube Aug 26, 2022

Shanghai-based 3D printing solution provider Prismlab China Ltd has raised RMB 200 million (USD 29.1...

Company Drug

Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company Drug

Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company

Novartis to Spin Off Sandoz, Focus on Innovative Drugs

Fineline Cube Aug 26, 2022

Swiss drugmaker Novartis announced plans to spin off its generic and biosimilar unit, Sandoz, to...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers

Fineline Cube Aug 26, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial...

Company

CStone Pharmaceuticals’ H1 2022 Revenue Jumps 229% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based CStone Pharmaceuticals (HKG: 2616) reported RMB 262 million (USD 49.4 million) in revenue for...

Company

Innovent Biologics’ H1 2022 Revenue Rises 15.3% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) reported RMB 2.24 billion (USD 326.4 million) in revenue...

Company

Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales

Fineline Cube Aug 25, 2022

China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for...

Company Drug

Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases

Fineline Cube Aug 25, 2022

Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...

Company Deals

eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership

Fineline Cube Aug 25, 2022

Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million...

Company Drug

Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial

Fineline Cube Aug 25, 2022

Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...

Company Deals

Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms

Fineline Cube Aug 25, 2022

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...

Company Policy / Regulatory

NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall

Fineline Cube Aug 25, 2022

The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...

Company Deals

Biocytogen and Merck KGaA Ink Global Deal for RenMice Platform Licensing

Fineline Cube Aug 25, 2022

Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global...

Company

3SBio Inc. Reports H1 2020 Revenue of RMB 3.091B, Net Profit Up 6.19%

Fineline Cube Aug 25, 2022

China-based 3SBio Inc. (HKG: 1530) reported its H1 2020 financial results, with revenue of RMB...

Posts pagination

1 … 673 674 675 … 707

Recent updates

  • Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia
  • MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development
  • Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals
  • IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million
  • Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Others

MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development

Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.